Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel + cisplatin + capecitabine induction followed by concurrent chemoradiotherapy with apatinib and camrelizumab in high-risk stage N3M0 nasopharyngeal carcinoma
ChiCTR2000032317Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel, cisplatin, capecitabine, Rivoceranib and camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Started May 2020; status: completed.
02
Drugs
paclitaxelcisplatincapecitabineRivoceranibcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000032317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032317.